Matching articles for "Claravis"
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • February 5, 2024; (Issue 1695)
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in...
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in 2016.
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • November 30, 2020; (Issue 1612)
Acne is common among adolescents and young adults,
but its prevalence appears to have increased in people
of all ages due to prolonged wearing of masks during
the COVID-19 pandemic. Guidelines for treatment...
Acne is common among adolescents and young adults,
but its prevalence appears to have increased in people
of all ages due to prolonged wearing of masks during
the COVID-19 pandemic. Guidelines for treatment of
acne were last published in 2016.
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • February 1, 2016; (Issue 1487)
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria...
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria Propionibacterium
acnes promotes development of acne lesions by
secreting chemotactic factors that attract leukocytes
to the follicle, causing inflammation.
In Brief: Absorica for Acne
The Medical Letter on Drugs and Therapeutics • January 21, 2013; (Issue 1408)
The oral retinoid isotretinoin (Accutane, and others) is the most effective drug available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product (Absorica – Cipher/Ranbaxy) for...
The oral retinoid isotretinoin (Accutane, and others) is the most effective drug available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product (Absorica – Cipher/Ranbaxy) for treatment of severe, recalcitrant nodular acne.
Isotretinoin can completely clear severe nodulocystic lesions, in some cases leading to remission that can persist for years after treatment is stopped. Mucocutaneous adverse effects include dry skin, dry eye, epistaxis, nasopharyngitis, cheilitis, alopecia, eczema, skin fragility and photosensitivity. Musculoskeletal symptoms, hypertriglyceridemia, hepatitis, pancreatitis, pseudotumor cerebri, depression and psychosis can occur.
The manufacturer’s package insert states that isotretinoin has been associated with inflammatory bowel disease, but a recent population-based cohort study found no significant association.2 The drug is a potent human teratogen (pregnancy category X); the prescriber, the pharmacist, the distributors, and the patient must register with iPLEDGE, a computer-based risk management program (www.ipledgeprogram.com).
The recommended dosage is 0.5 to 1 mg/kg/day given in 2 divided doses for 15-20 weeks. Unlike other formulations of isotretinoin, which are highly lipophilic and must be taken with a high-fat meal to achieve therapeutic plasma levels, Absorica can be taken with or without food, but serum concentrations are higher when it is taken with food. It should be taken with a full glass of water to reduce the risk of esophageal irritation. Absorica has not been shown to be more effective or better tolerated than generic formulations of isotretinoin.
1. Drugs for acne, rosacea and psoriasis. Treat Guidel Med Lett 2013; 11:1.
2. RO Alhusayen et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2012 Oct 25 (epub).
Download complete U.S. English article
Isotretinoin can completely clear severe nodulocystic lesions, in some cases leading to remission that can persist for years after treatment is stopped. Mucocutaneous adverse effects include dry skin, dry eye, epistaxis, nasopharyngitis, cheilitis, alopecia, eczema, skin fragility and photosensitivity. Musculoskeletal symptoms, hypertriglyceridemia, hepatitis, pancreatitis, pseudotumor cerebri, depression and psychosis can occur.
The manufacturer’s package insert states that isotretinoin has been associated with inflammatory bowel disease, but a recent population-based cohort study found no significant association.2 The drug is a potent human teratogen (pregnancy category X); the prescriber, the pharmacist, the distributors, and the patient must register with iPLEDGE, a computer-based risk management program (www.ipledgeprogram.com).
The recommended dosage is 0.5 to 1 mg/kg/day given in 2 divided doses for 15-20 weeks. Unlike other formulations of isotretinoin, which are highly lipophilic and must be taken with a high-fat meal to achieve therapeutic plasma levels, Absorica can be taken with or without food, but serum concentrations are higher when it is taken with food. It should be taken with a full glass of water to reduce the risk of esophageal irritation. Absorica has not been shown to be more effective or better tolerated than generic formulations of isotretinoin.
1. Drugs for acne, rosacea and psoriasis. Treat Guidel Med Lett 2013; 11:1.
2. RO Alhusayen et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2012 Oct 25 (epub).
Download complete U.S. English article
Drugs for Acne, Rosacea and Psoriasis
The Medical Letter on Drugs and Therapeutics • January 1, 2013; (Issue 125)
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria...
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria Propionibacterium
acnes promote development of acne lesions by secreting
chemotactic factors that attract leukocytes to the
follicle, causing inflammation.